Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Movement: Quantinuum surges on October 15 as Morgan Stanley upgrades rating and quantum computing news

US Stock Movement: Quantinuum surges on October 15 as Morgan Stanley upgrades rating and quantum computing news

Bitget异动解读Bitget异动解读2026/10/15 14:31
Show original

Quantinuum October 15 Surge Analysis

Keywords: Morgan Stanley rating upgrade, quantum computing

1. On October 15, Morgan Stanley upgraded Quantinuum’s rating from “Equal-weight” to “Overweight,” and listed it as its top pick in the quantum computing sector; the target price was lowered from $78 to $62.

2. On October 15, Morgan Stanley stated that Quantinuum demonstrated outstanding performance in technological progress and execution capabilities, leading in progress and with an excellent execution track record among pure quantum computing companies; its projected 2030 revenue multiple is the lowest among peers. The institution forecasts the global quantum computing market could exceed $100 billion by 2040.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%